Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1M | 1M |
| Gross Profit | -87K | 0 | -302K | 1M | 1M |
| Operating Income | -9M | -9M | -15M | -37M | -66M |
| EBITDA | -9M | -8M | -14M | -35M | -64M |
| Net Income | -8M | -11M | -21M | -33M | -64M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.63
-0.91% today
1Y Change
-36.51%
Window
Jun 26, 2025 → Jun 16, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BeyondSpring Inc. (BYSI) is a Healthcare stock with a market cap of $60.00M. The stock last traded around $1.63 and down 36.5% across the available one-year price window (Jun 26, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +28.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +28.6%, free cash flow -20.4% with operating margin 0.0% and ROIC -70.6%. Stock Foundry combines BYSI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BYSI
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BYSI Max Drawdown
-49.60%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BYSI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
+0.0% YoY
FY Net Income
-$64.2M
-92.9% YoY
Free Cash Flow
-$50.1M
-77.7% YoY
Revenue Growth
+0.0%
EPS Growth
+28.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1M | 1M |
| Gross Profit | -87K | 0 | -302K | 1M | 1M |
| Operating Income | -9M | -9M | -15M | -37M | -66M |
| EBITDA | -9M | -8M | -14M | -35M | -64M |
| Net Income | -8M | -11M | -21M | -33M | -64M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8M | 3M | 15M | 34M | 42M |
| Total Assets | 26M | 34M | 25M | 46M | 82M |
| Total Liabilities | 50M | 49M | 48M | 49M | 61M |
| Shareholder Equity | -32M | -33M | -27M | -6M | 27M |
| Total Debt | 320K | 589K | 847K | 5M | 4M |
| Net Debt | -7M | -2M | -14M | -29M | -38M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
47M
-67.8% YoY
Capital Expenditures
3M
-8264.7% YoY
Free Cash Flow
50M
-77.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
26.1%
Debt / Equity
-0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.